Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
Individuals who are immunocompromised (IC) due to therapy or underlying disease are at increased risk of herpes zoster (HZ). This study evaluates the public health impact of recombinant zoster vaccine (RZV) relative to no HZ vaccination for the prevention of HZ among adults aged ≥18 years diagnosed...
Saved in:
Main Authors: | Desmond Curran (Author), Brandon J. Patterson (Author), Justin Carrico (Author), Ahmed Salem (Author), Elizabeth M. La (Author), Stéphane Lorenc (Author), Katherine A. Hicks (Author), Sara Poston (Author), Christopher F. Carpenter (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
by: Nikolaos Giannelos, et al.
Published: (2023) -
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
by: Desmond Curran, et al.
Published: (2019) -
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
by: Agnes Mwakingwe-Omari, et al.
Published: (2023) -
Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States
by: Desmond Curran, et al.
Published: (2022) -
Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination
by: Jean-Etienne Poirrier, et al.
Published: (2022)